Reducing a protein shifts gene activity in human immune cells
Experiments in lab-grown brain immune cells shifted gene activity away from disease-associated states and toward inflammatory responses, with weaker responses in cells carrying an Alzheimer’s-linked gene variant.
Our read
Mechanisms- Studied:
- Preprint: experiments in human cells
- In the record:
- One of 6 papers on DAB2 on record: 1 with results in people, 1 in animals.
Editor of record: Boris Djordjevic · AgingResearch.News
Human microglia, the brain’s immune cells, were grown from stem cells for experiments that reduced DAB2, an adaptor protein that helps other proteins work together. Researchers compared cells with matched genetic backgrounds but different versions of APOE, a gene involved in Alzheimer’s disease risk.
Reducing DAB2 shifted gene activity away from networks associated with disease-linked microglial states and toward states responsive to inflammatory signals. Cells carrying two copies of APOE4, a version linked to Alzheimer’s risk, showed a weaker gene-activity response to DAB2 reduction. The authors interpreted this as consistent with an interaction between the pathways involving APOE and DAB2. They identified DAB2 as a regulator of microglial state changes and a modifier of dementia-risk gene networks.
Why it matters
The brain’s immune cells may help connect inherited Alzheimer’s risk with inflammation and the clearance of amyloid-beta, a protein involved in the disease.
Caveats
Experiments in lab-grown microglia leave open whether reducing DAB2 would have the same effects within a living human brain. The work is a preprint and has not been peer-reviewed.
The paper
University College London
bioRxiv, Nov 13, 2026, Open access, CC BY, Preprint, not yet peer-reviewed
Comments
Be the first to comment.